Alexandros G .Sfakianakis,ENT,Anapafeos 5 Agios Nikolaos Crete 72100 Greece,00302841026182

Τρίτη 20 Οκτωβρίου 2020

ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis

Cancer shared this article with you from Inoreader

41417_2020_245_Fig1_HTML.png

Cancer Gene Therapy, Published online: 17 October 2020; doi:10.1038/s41417-020-00245-w

ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis
View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις